Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Magenta Therapeutics Inc (MGTA)

Magenta Therapeutics Inc (MGTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 277,178
  • Shares Outstanding, K 39,484
  • Annual Sales, $ 0 K
  • Annual Income, $ -76,770 K
  • 60-Month Beta 2.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.53
  • Number of Estimates 3
  • High Estimate -0.51
  • Low Estimate -0.55
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -10.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.83 +3.07%
on 07/30/20
9.30 -24.30%
on 07/07/20
-0.93 (-11.67%)
since 07/02/20
3-Month
6.83 +3.07%
on 07/30/20
11.65 -39.57%
on 05/08/20
-1.79 (-20.27%)
since 05/01/20
52-Week
5.76 +22.22%
on 03/23/20
16.19 -56.52%
on 12/24/19
-5.59 (-44.26%)
since 08/02/19

Most Recent Stories

More News
Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session

Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

MGTA : 7.21 (+2.71%)
APLT : 25.81 (+0.04%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact ...

MGTA : 7.21 (+2.71%)
MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm

, /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:...

MGTA : 7.21 (+2.71%)
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta's...

MGTA : 7.21 (+2.71%)
BEAM : 18.97 (-1.91%)
Magenta Therapeutics' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Magenta Therapeutics.

MGTA : 7.21 (+2.71%)
AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

--Under the collaboration, AVROBIO and Magenta will jointly evaluate MGTA-117 in conjunction with one or more of AVROBIO's investigational gene therapies

AVRO : 16.88 (-0.41%)
MGTA : 7.21 (+2.71%)
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across...

JPM : 96.96 (+0.33%)
MGTA : 7.21 (+2.71%)
Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is...

JPM : 96.96 (+0.33%)
MGTA : 7.21 (+2.71%)
Magenta Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

MGTA : 7.21 (+2.71%)
Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today...

JPM : 96.96 (+0.33%)
MGTA : 7.21 (+2.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade MGTA with:

Business Summary

Magenta Therapeutics Inc. is a clinical-stage biotechnology company. It engaged in developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. Magenta Therapeutics Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 7.26
1st Resistance Point 7.14
Last Price 7.21
1st Support Level 6.90
2nd Support Level 6.78

See More

52-Week High 16.19
Fibonacci 61.8% 12.21
Fibonacci 50% 10.98
Fibonacci 38.2% 9.74
Last Price 7.21
52-Week Low 5.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar